RITSUKO KOMAKI to Adenocarcinoma
This is a "connection" page, showing publications RITSUKO KOMAKI has written about Adenocarcinoma.
Connection Strength
1.872
-
Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial. J Thorac Oncol. 2017 02; 12(2):375-382.
Score: 0.151
-
Esophageal cancer dose escalation using a simultaneous integrated boost technique. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):468-74.
Score: 0.100
-
Esophageal cancer located at the neck and upper thorax treated with concurrent chemoradiation: a single-institution experience. J Thorac Oncol. 2006 Mar; 1(3):252-9.
Score: 0.072
-
Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters. Int J Radiat Oncol Biol Phys. 2003 Dec 01; 57(5):1317-22.
Score: 0.062
-
Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma. Ann Surg. 2018 08; 268(2):289-295.
Score: 0.043
-
Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. Oncology. 2018; 94(6):345-353.
Score: 0.042
-
Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience. Cancer. 2017 Nov 01; 123(21):4106-4113.
Score: 0.040
-
The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol. 2017 08; 124(2):318-324.
Score: 0.040
-
Lymphocyte Nadir and Esophageal Cancer Survival Outcomes After Chemoradiation Therapy. Int J Radiat Oncol Biol Phys. 2017 09 01; 99(1):128-135.
Score: 0.039
-
18F-FDG PET Response After Induction Chemotherapy Can Predict Who Will Benefit from Subsequent Esophagectomy After Chemoradiotherapy for Esophageal Adenocarcinoma. J Nucl Med. 2017 11; 58(11):1756-1763.
Score: 0.039
-
7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial. Cancer. 2017 Aug 15; 123(16):3031-3039.
Score: 0.039
-
Long-Term Outcomes of Salvage Stereotactic Ablative?Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial. J Thorac Oncol. 2017 06; 12(6):983-992.
Score: 0.039
-
Final Results of NRG Oncology RTOG 0246: An?Organ-Preserving Selective Resection Strategy in?Esophageal Cancer Patients Treated with Definitive?Chemoradiation. J Thorac Oncol. 2017 02; 12(2):368-374.
Score: 0.038
-
Factors Predictive of Improved Outcomes With Multimodality Local Therapy After Palliative Chemotherapy for Stage IV Esophageal Cancer. Am J Clin Oncol. 2016 06; 39(3):228-35.
Score: 0.037
-
Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data. Eur Respir J. 2015 Dec; 46(6):1751-61.
Score: 0.035
-
Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):317-24.
Score: 0.034
-
Distribution of Resistant Esophageal Adenocarcinoma in the Resected Specimens of Clinical Stage III Patients after Chemoradiation: Its Clinical Implications. Oncology. 2015; 89(2):65-9.
Score: 0.034
-
Geographic distribution of regional metastatic nodes affects the outcome of trimodality-eligible patients with esophageal adenocarcinoma. Oncology. 2015; 88(6):332-6.
Score: 0.034
-
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015 Feb; 16(2):187-99.
Score: 0.033
-
A validated miRNA profile predicts response to therapy in esophageal adenocarcinoma. Cancer. 2014 Dec 01; 120(23):3635-41.
Score: 0.032
-
Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. J Natl Compr Canc Netw. 2014 Aug; 12(8):1139-44.
Score: 0.032
-
Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role? J Thorac Oncol. 2014 Aug; 9(8):1202-6.
Score: 0.032
-
Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer. Ann Surg Oncol. 2014 Jan; 21(1):306-14.
Score: 0.031
-
Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. J Clin Oncol. 2013 Dec 01; 31(34):4306-10.
Score: 0.031
-
Incidence of brain metastases after trimodality therapy in patients with esophageal or gastroesophageal cancer: implications for screening and surveillance. Oncology. 2013; 85(4):204-7.
Score: 0.030
-
Propensity-based matching between esophagogastric cancer patients who had surgery and who declined surgery after preoperative chemoradiation. Oncology. 2013; 85(2):95-9.
Score: 0.030
-
Surgery is an essential component of multimodality therapy for patients with locally advanced esophageal adenocarcinoma. J Gastrointest Surg. 2013 Aug; 17(8):1359-69.
Score: 0.030
-
Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol. 2013 Jun; 52(5):1002-9.
Score: 0.028
-
Quantifying the interfractional displacement of the gastroesophageal junction during radiation therapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012 Jun 01; 83(2):e273-80.
Score: 0.027
-
Proton beam therapy and concurrent chemotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012 Jul 01; 83(3):e345-51.
Score: 0.027
-
A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246. Int J Radiat Oncol Biol Phys. 2012 Apr 01; 82(5):1967-72.
Score: 0.026
-
Combined modality therapy of cT2N0M0 esophageal cancer: the University of Texas M. D. Anderson Cancer Center experience. Cancer. 2011 Mar 01; 117(5):925-30.
Score: 0.025
-
Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. Cancer. 2010 Apr 01; 116(7):1656-63.
Score: 0.024
-
Impact of tumor length on long-term survival of pT1 esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2009 Oct; 138(4):831-6.
Score: 0.022
-
Frequent loss of heterozygosity of chromosome 1q in esophageal adenocarcinoma: loss of chromosome 1q21.3 is associated with shorter overall survival. Cancer. 2009 Apr 01; 115(7):1576-85.
Score: 0.022
-
Patterns of care and locoregional treatment outcomes in older esophageal cancer patients: The SEER-Medicare Cohort. Int J Radiat Oncol Biol Phys. 2009 Jun 01; 74(2):482-9.
Score: 0.022
-
Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation. Cancer. 2009 Feb 01; 115(3):624-30.
Score: 0.022
-
Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung. Clin Cancer Res. 2008 Dec 01; 14(23):7832-7.
Score: 0.022
-
Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma. Int J Radiat Oncol Biol Phys. 2007 Feb 01; 67(2):389-96.
Score: 0.019
-
Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer. 2007 Jan 01; 109(1):125-34.
Score: 0.019
-
Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response. Clin Cancer Res. 2006 Nov 01; 12(21):6565-72.
Score: 0.019
-
The significance of neuroendocrine differentiation in adenocarcinoma of the esophagus and esophagogastric junction after preoperative chemoradiation. Cancer. 2006 Oct 01; 107(7):1467-74.
Score: 0.019
-
The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma. Cancer. 2006 Sep 01; 107(5):967-74.
Score: 0.019
-
Tumor-specific apoptotic gene targeting overcomes radiation resistance in esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys. 2006 Apr 01; 64(5):1482-94.
Score: 0.018
-
The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer. 2006 Mar 01; 106(5):1017-25.
Score: 0.018
-
Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy. Cancer. 2006 Feb 01; 106(3):552-8.
Score: 0.018
-
Endoscopic ultrasonography-identified celiac adenopathy remains a poor prognostic factor despite preoperative chemoradiotherapy in esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2006 Jan; 131(1):65-72.
Score: 0.018
-
Polymorphism at the 3'-UTR of the thymidylate synthase gene: a potential predictor for outcomes in Caucasian patients with esophageal adenocarcinoma treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys. 2006 Mar 01; 64(3):700-8.
Score: 0.018
-
Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg. 2005 May; 241(5):810-7; discussion 817-20.
Score: 0.017
-
Differential response to preoperative chemoradiation and surgery in esophageal adenocarcinomas based on presence of Barrett's esophagus and symptomatic gastroesophageal reflux. Ann Thorac Surg. 2005 May; 79(5):1716-23.
Score: 0.017
-
Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys. 2005 Feb 01; 61(2):318-28.
Score: 0.017
-
Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. Int J Radiat Oncol Biol Phys. 2004 Dec 01; 60(5):1484-93.
Score: 0.017
-
2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer. 2004 Oct 15; 101(8):1776-85.
Score: 0.016
-
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg. 2004 Oct; 78(4):1152-60; discussion 1152-60.
Score: 0.016
-
Treatment outcomes of resected esophageal cancer. Ann Surg. 2002 Sep; 236(3):376-84; discussion 384-5.
Score: 0.014
-
INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002 Mar 01; 20(5):1167-74.
Score: 0.014
-
A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer. J Thorac Oncol. 2017 06; 12(6):1001-1010.
Score: 0.010
-
PDL1 Regulation by p53 via miR-34. J Natl Cancer Inst. 2016 Jan; 108(1).
Score: 0.009
-
Comparison of locoregional versus extended locoregional radiation volumes for patients with nonmetastatic gastro-esophageal junction carcinomas. J Thorac Oncol. 2015 Mar; 10(3):518-26.
Score: 0.008
-
Definitive reirradiation for locoregionally recurrent non-small cell lung cancer with proton beam therapy or intensity modulated radiation therapy: predictors of high-grade toxicity and survival outcomes. Int J Radiat Oncol Biol Phys. 2014 Nov 15; 90(4):819-27.
Score: 0.008
-
Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes. Int J Radiat Oncol Biol Phys. 2014 Aug 01; 89(5):1084-1091.
Score: 0.008
-
Predictors of postoperative complications after trimodality therapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2013 Aug 01; 86(5):885-91.
Score: 0.008
-
Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis. Int J Radiat Oncol Biol Phys. 2012 Sep 01; 84(1):e61-7.
Score: 0.007
-
Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy. BMC Cancer. 2010 Aug 16; 10:431.
Score: 0.006
-
Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther. 2007 Feb; 6(2):471-83.
Score: 0.005
-
Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer. 2005 Dec 01; 104(11):2365-72.
Score: 0.004
-
Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. Cancer. 2005 Oct 15; 104(8):1620-6.
Score: 0.004
-
Preoperative chemoradiotherapy prior to esophagectomy in elderly patients is not associated with increased morbidity. Ann Thorac Surg. 2005 Feb; 79(2):391-7; discussionn 391-7.
Score: 0.004
-
Endoscopic ultrasound after preoperative chemoradiation can help identify patients who benefit maximally after surgical esophageal resection. Am J Gastroenterol. 2004 Jul; 99(7):1258-66.
Score: 0.004
-
Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer. 2004 Jun 01; 100(11):2347-54.
Score: 0.004
-
Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer. Int J Radiat Oncol Biol Phys. 2003 Sep 01; 57(1):120-7.
Score: 0.004